Background: We aimed to assess medication risks and determine factors influencing the health-related quality of life (HRQOL) in cancer inpatients. Methods: A retrospective analysis was conducted to identify drug-related problems (DRPs) based on medication reviews, including patient-reported outcomes (PROs). Multiple linear regression analyses were performed to identify sociodemographic, disease-related, and drug therapy-related factors influencing changes from hospital admission to discharge in the scales of the EORTC QLQ-C30 questionnaire. Results: A total of 162 inpatients with various hematological and solid cancer diseases was analyzed. Patients received a mean of 11.6 drugs and 92.6% of patients exhibited polymedication resulting in a mean of 4.0 DRPs per patient. Based on PRO data, 21.5% of DRPs were identified. Multiple linear regression models described the variance of the changes in global HRQOL and physical function in a weak-to-moderate way. While drug therapy-related factors had no influence, relapse status and duration of hospital stay were identified as significant covariates for global HRQOL and physical function, respectively. Conclusion: This analysis describes underlying DRPs in a German cancer inpatient population. PROs provided valuable information for performing medication reviews. The multiple linear regression models for global HRQOL and physical function provided explanations for changes during hospital stay.
背景：本研究旨在评估癌症住院患者的用药风险，并确定影响其健康相关生活质量（HRQOL）的因素。方法：通过回顾性分析，基于包含患者报告结局（PROs）的用药审查，识别药物相关问题（DRPs）。采用多元线性回归分析，探讨社会人口学、疾病相关及药物治疗相关因素对EORTC QLQ-C30量表从入院到出院期间评分变化的影响。结果：共纳入162例患有各类血液系统及实体肿瘤的住院患者进行分析。患者平均用药11.6种，92.6%的患者存在多重用药情况，平均每例患者发生4.0个DRPs。基于PRO数据识别出的DRPs占21.5%。多元线性回归模型对整体HRQOL及躯体功能变化的解释力度为弱至中度。虽然药物治疗相关因素未显示影响，但疾病复发状态和住院时长分别被确定为整体HRQOL和躯体功能的重要协变量。结论：本分析揭示了德国癌症住院患者群体中潜在的DRPs。PROs为实施用药审查提供了有价值的信息。针对整体HRQOL和躯体功能建立的多元线性回归模型为住院期间的变化提供了合理解释。
Medication Risks and Their Association with Patient-Reported Outcomes in Inpatients with Cancer
肿瘤(癌症)患者之家